What is Northland Capmk’s Estimate for HRTX FY2026 Earnings?

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Equities research analysts at Northland Capmk issued their FY2026 earnings estimates for Heron Therapeutics in a research report issued to clients and investors on Tuesday, November 4th. Northland Capmk analyst C. Byrnes anticipates that the biotechnology company will earn ($0.05) per share for the year. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.13) per share.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03). The business had revenue of $38.21 million during the quarter, compared to analysts’ expectations of $39.03 million. Heron Therapeutics has set its FY 2025 guidance at EPS.

Other equities analysts have also issued research reports about the stock. Jefferies Financial Group restated a “buy” rating on shares of Heron Therapeutics in a research report on Tuesday. Wall Street Zen cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Wednesday, October 8th. Needham & Company LLC reduced their target price on Heron Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday, August 8th. Finally, Zacks Research upgraded Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 7th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $4.50.

Heron Therapeutics Trading Down 3.2%

NASDAQ:HRTX traded down $0.04 during mid-day trading on Friday, reaching $1.07. 743,401 shares of the stock were exchanged, compared to its average volume of 1,685,787. The business has a fifty day moving average price of $1.26 and a 200 day moving average price of $1.69. The firm has a market capitalization of $195.23 million, a PE ratio of -53.25 and a beta of 1.30. Heron Therapeutics has a 1-year low of $1.04 and a 1-year high of $2.68.

Institutional Investors Weigh In On Heron Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of HRTX. JPMorgan Chase & Co. increased its position in Heron Therapeutics by 35.6% during the third quarter. JPMorgan Chase & Co. now owns 1,292,444 shares of the biotechnology company’s stock worth $1,628,000 after buying an additional 339,364 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in shares of Heron Therapeutics by 5,541.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 24,088 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 23,661 shares in the last quarter. Tejara Capital Ltd increased its holdings in shares of Heron Therapeutics by 1.6% during the 3rd quarter. Tejara Capital Ltd now owns 4,589,715 shares of the biotechnology company’s stock valued at $5,783,000 after acquiring an additional 72,300 shares during the last quarter. New York State Common Retirement Fund raised its stake in shares of Heron Therapeutics by 46.4% in the 3rd quarter. New York State Common Retirement Fund now owns 2,576,716 shares of the biotechnology company’s stock valued at $3,247,000 after acquiring an additional 816,671 shares in the last quarter. Finally, CWM LLC lifted its holdings in Heron Therapeutics by 738.0% in the 3rd quarter. CWM LLC now owns 45,015 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 39,643 shares during the last quarter. Institutional investors and hedge funds own 80.01% of the company’s stock.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.